Last updated on February 2019

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

---

Brief description of study

The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period. It is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.

Detailed Study Description

This study will have a main 24-week treatment period and a 28-week extension period of treatment.